Updates on Vaccine Efficacy in Multiple Sclerosis

Stephen Krieger, MD: Well, let’s turn to our final topic. And I think it’s very nice that we’ve arrived at a point where we can spend 90 minutes together talking about lots of issues in MS [multiple sclerosis] treatments and MS management and save the intersection of MS and COVID-19 for the last 5 or so minutes. For a long time, we spent a lot of our time talking to patients just about that. So it’s nice to be able to get back to our true commitments to keeping people with MS safe and free of disease activity and minimizing progression and hopefully have COVID-19-related concerns be minimal. But we still have some.